

Recent Results in Cancer Research
P. M. Schlag · H.-J. Senn *Series Editors*

Andrew T. Chan · Elmar Detering
Editors

Prospects for Chemoprevention of Colorectal Neoplasia

Emerging Role of Anti-Inflammatory Drugs

Indexed in PubMed/Medline

 Springer

Recent Results in Cancer Research

Volume 191

Managing Editors

P. M. Schlag, Berlin, Germany

H.-J. Senn, St. Gallen, Switzerland

Associate Editors

P. Kleihues, Zürich, Switzerland

F. Stiefel, Lausanne, Switzerland

B. Groner, Frankfurt, Germany

A. Wallgren, Göteborg, Sweden

Founding Editor

P. Rentchnik, Geneva, Switzerland

For further volumes:

<http://www.springer.com/series/392>

Andrew T. Chan · Elmar Detering
Editors

Prospects for Chemoprevention of Colorectal Neoplasia

Emerging Role of Anti-Inflammatory
Drugs

Editors

Andrew T. Chan
Division of Gastroenterology
Massachusetts General Hospital
Harvard Medical School
Boston, MA
USA

Elmar Detering
Global Medical Affairs (Primary Care)
Bayer Pharma AG, Berlin
Germany

ISSN 0080-0015

ISBN 978-3-642-30330-2 ISBN 978-3-642-30331-9 (eBook)

DOI 10.1007/978-3-642-30331-9

Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2012943957

© Springer-Verlag Berlin Heidelberg 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Contents

An Emerging Role for Anti-inflammatory Agents for Chemoprevention.	1
References	4
Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia . . .	7
1 Molecular Basis of Colorectal Adenoma and Carcinoma	9
1.1 Genetic Basis of Adenoma-Carcinoma Sequence.	9
1.2 Adenomatous Polyposis Coli.	10
1.3 The Microsatellite Instability Pathway in CRC	11
1.4 The Epigenetic Pathway in CRC	12
1.5 COX-2/mPGES-1 Pathway	12
1.6 Prostaglandin Transporters in CRC	16
1.7 Epidermal Growth Factor Receptor Pathway.	16
1.8 Peroxisome Proliferator-Activated Receptors.	17
1.9 Tumor Microenvironment in Colorectal Carcinogenesis	18
2 COX-2 Gene Expression in CRC	18
2.1 Transcriptional Regulation	19
2.2 Post-transcriptional Regulation and the 3' Untranslated Region.	21
2.3 AU-Rich Elements and ARE-Binding Proteins	22
2.4 MicroRNAs	26
3 Conclusions	29
References	30
Mode of Action of Aspirin as a Chemopreventive Agent.	39
1 Introduction	41
2 Mechanisms of Action of Aspirin	42
2.1 Historical Overview of Aspirin and its Mechanism of Action (Box. 1).	42
2.2 Insights into the Mechanism of Inhibition of COXs by Aspirin.	44
3 Pharmacology/Pharmacokinetic of Aspirin	49

3.1	COX-Isozyme Selectivity in Vitro	49
3.2	Pharmacokinetic	50
3.3	Determinants of Achieved COX-Isozyme Selectivity by Clinical Doses of Aspirin.	52
4	Role of Platelets in Tumorigenesis	53
4.1	Platelet-Mediated Mechanisms in Tumorigenesis and Metastasis.	53
4.2	Role of Platelet COX-1 in Aspirin Chemoprevention.	56
5	COX-Independent Mechanisms of Aspirin Chemoprevention	57
5.1	Inhibition of NF- κ B	57
5.2	Interruption of Extracellular Signal-Regulated Kinases	59
5.3	Induction of Apoptosis by Caspase Activation	59
5.4	Inhibition of Wnt/ β -Catenin Pathway.	59
6	Aspirin-Mediated Acetylation of Extra-COX Proteins	59
7	Conclusions	60
	References	61
	Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials	67
1	Introduction	69
2	Pharmacology of tNSAIDs and Coxibs	76
3	Efficacy of Coxibs in CRC Chemoprevention Trials	77
4	CV Toxicity of Coxibs.	80
4.1	Risk Estimates: Data from Trials and Observational Studies.	80
4.2	Mechanisms of CV Toxicity of Coxibs	83
4.3	Ongoing Randomized Clinical Trials with Coxibs/NSAIDs.	85
5	Conclusions and Perspectives	86
	References	87
	COX-2 Active Agents in the Chemoprevention of Colorectal Cancer	95
	References	102
	New NSAID Targets and Derivatives for Colorectal Cancer Chemoprevention	105
1	Introduction	106
2	Targeting COX-2.	109
3	COX-Independent Targets	110
3.1	Inhibition of cGMP PDEs.	110
3.2	Generation of Reactive Oxygen Species.	112
3.3	Downregulation of Survivin	113
3.4	Other COX-Independent Targets	114
4	Conclusions	115
	References	117

Aspirin in Prevention of Sporadic Colorectal Cancer: Current Clinical Evidence and Overall Balance of Risks and Benefits	121
1 Introduction	122
2 Aspirin in Prevention of Colorectal Cancer.	122
2.1 Observational Studies.	122
2.2 Randomised Controlled Trials	125
3 Effects on Other Cancers	131
4 Overall Balance of Risk and Benefit	135
5 Summary and Outstanding Issues	137
References	139
Nutritional Agents with Anti-inflammatory Properties in Chemoprevention of Colorectal Neoplasia	143
1 Naturally Occurring Substances Used as Pharmaceutical Preparations—‘Nutraceuticals’	144
2 Anti-inflammatory Agents for Prevention and Treatment of CRC	145
3 Anti-inflammatory Nutraceuticals with Evidence of Anti-CRC Activity.	145
3.1 Omega-3 PUFAs	145
3.2 Curcumin	149
3.3 Resveratrol	151
3.4 Other Dietary Polyphenols	152
3.5 Other Natural Anti-inflammatory Agents with CRC Chemopreventative Efficacy	152
4 Summary	153
References	153
Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC)	157
1 Introduction	159
2 CAPP1	163
2.1 CAPP1 Trial Design	164
2.2 CAPP1 Endpoint Ascertainments.	165
2.3 CAPP1 Laboratory and Statistical Methods.	165
2.4 CAPP1 Results	166
2.5 CAPP1 Toxicity	168
2.6 CAPP1 Conclusions.	169
3 Chemoprevention in Lynch Syndrome: CAPP2.	170
3.1 CAPP2 Trial Design	172
3.2 CAPP2 Endpoint Ascertainments.	172
3.3 CAPP2 Statistical Methods	172
3.4 CAPP2 Results	175
3.5 CAPP2 Toxicity	178
3.6 CAPP2 Discussion.	179

4	CAPP3	180
5	Conclusion	180
	References	181

An Emerging Role for Anti-inflammatory Agents for Chemoprevention

Andrew T. Chan and Elmar Detering

Abstract

There have been a number of promising recent developments in the prevention of colorectal cancer. This book examines in detail important aspects of the current status of and future prospects for chemoprevention of colorectal tumors, particularly using anti-inflammatory drugs. Research into the mechanisms that lead from early colorectal adenoma to colorectal cancer is discussed. The role and modes of action of available anti-inflammatory drugs, such as aspirin, celecoxib, and sulindac are described and recent data from trials of aspirin are reviewed. In addition, the possible impact of nutritional agents with anti-inflammatory properties is considered, and strategies applicable in those with a high level of genetic risk are evaluated. An important feature of the book is its interdisciplinary perspective, offering highly relevant information for gastroenterologists, internists, general practitioners, oncologists, colorectal and gastroenterological surgeons, and public health practitioners.

Contents

References.....	4
-----------------	---

*Prospects for Chemoprevention of Colorectal Neoplasia—
Emerging Role of Anti-Inflammatory Drugs.?*

A. T. Chan (✉)

Division of Gastroenterology Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA

e-mail: achan@partners.org

E. Detering

Global Medical Affairs (Primary Care), Bayer Pharma AG, 13465 Berlin, Germany

A. T. Chan and E. Detering (eds.), *Prospects for Chemoprevention of Colorectal Neoplasia*, 1

Recent Results in Cancer Research 191, DOI: 10.1007/978-3-642-30331-9_1,

© Springer-Verlag Berlin Heidelberg 2013

Colorectal cancer (CRC) is a compelling example of a chronic disease for which there is a critical need for novel preventive strategies. CRC is the second most common cancer in developed countries, with about 1 million new cases and 600,000 deaths worldwide each year. The incidence rates (IR) of CRC vary markedly worldwide, being highest in Europe, North America, and Oceania. The lifetime risk of CRC in Western populations such as the United States (US) is 5%. In Europe, there were 412,900 new cases and 217,400 deaths due to CRC during 2006. While the incidence of CRC has been declining in the US since the 1980s, several countries, especially those that are economically transitioning to a more urbanized/westernized lifestyle, have been seeing important increases (GLOBOCAN 2008).

Given the poor outcomes of advanced CRC, considerable emphasis has been focused on prevention through population screening for the early detection of CRCs and adenomatous polyps, the precursor for the vast majority of cancers. Although screening modalities such as fecal occult blood testing and endoscopy are efficacious, patient uptake is often suboptimal, limiting its real-world effectiveness. Thus, there is a clear imperative to consider alternative preventative strategies, including chemoprevention.

'Chemoprevention' describes the use of drugs or other (including natural) agents to inhibit or prevent the development or progression of malignant changes in cells. An important milestone in the evolution of agents for chemoprevention was the discovery of the "inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs" by Sir John Vane in 1971, who received the Nobel Prize in 1982 (together with Bergstrom and Samuelsson) (Vane 1971). Their work was seminal in establishing cyclooxygenase (COX), also known as prostaglandin synthase (PTGS), as the principle target enzyme for aspirin and aspirin-like drugs now commonly known as non-steroidal anti-inflammatory drugs (NSAIDs) (Vane 1982). The COX-1 and COX-2 isoenzymes are responsible for formation of prostaglandins and related biologically active substances, important mediators of inflammation.

Historically, *in vitro* and animal studies with aspirin and NSAIDs as potential chemopreventive agents began early in the 1980s. In humans, sulindac was among the first drugs with demonstrated chemopreventive efficacy in studies of patients with familial adenomatous polyposis (FAP), an autosomal dominant hereditary CRC syndrome that has provided tremendous insight into the pathogenesis of sporadic colorectal cancer. The key distinguishing feature of classic FAP is the development of hundreds to thousands of adenomatous polyps throughout the colon, often beginning as early as the second decade of life. Colorectal adenocarcinomas inevitably develop in FAP patients, typically by age 40. In early studies, sulindac treatment caused marked regression of polyps in patients with FAP (Giardiello et al. 1993).

The FAP model also paved the way for further analysis of the NSAIDs celecoxib and rofecoxib, selective COX-2 inhibitors, as potential chemopreventatives in colorectal adenoma and cancer (Steinbach et al. 2000; Hallak et al. 2003; Arber et al. 2006; Bertagnolli et al. 2006). Despite their demonstrated efficacy in well-designed clinical trials of both FAP and sporadic adenoma, the occurrence of

cardiovascular events associated with these agents has dampened enthusiasm for their routine use for chemoprevention.

Concerns about NSAID-associated cardiovascular toxicity have refocused attention on the chemopreventive properties of aspirin, the oldest of the “modern” anti-inflammatory drugs. Aspirin not only has a favorable cardiovascular profile but is already widely used for the prevention of cardiovascular events. Several epidemiological studies (Chan 2011), randomized controlled trials (RCTs) of colon polyp recurrence (Cole et al. 2009; Chan et al. 2007; Baron et al. 2003; Sandler et al. 2003; Benamouzig et al. 2003; Logan et al. 2008), and RCTs in patients with hereditary CRC syndromes (Burn et al. 2011a, 2011b; Chan et al. 2005, 2008, 2009), have shown that aspirin reduces incidence of colorectal neoplasia. In five cardiovascular-prevention RCTs, Rothwell and colleagues previously observed that daily aspirin at any dose reduced risk of CRC by 24 % and of CRC-associated mortality by 35 % after a delay of 8–10 years (Rothwell et al. 2010). Thus, aspirin may be currently the most promising agent considering it demonstrated effectiveness and its favorable cardiovascular safety profile. Because CRC and vascular disease have overlapping risk factors (e.g., diabetes, obesity, physical inactivity), use of aspirin for the dual purpose of cancer and vascular disease prevention has considerable appeal. Moreover, emerging data show that aspirin may be associated with a lower risk of death from cancer of sites other than the colorectum (Rothwell et al. 2011, 2012). Thus, despite aspirin’s known association with gastrointestinal toxicity, the overwhelming benefits of aspirin for a wide range of the most common chronic diseases could overall tip the scales in favor of aspirin as the chemopreventive agent of choice for many individuals Chan et al. (2012) and Avivi et al. (2012)

Our knowledge about the mechanism underlying the anti-neoplastic benefit of these anti-inflammatory agents is growing, but yet incomplete. At present, the known effects of these agents in inhibiting COX-1 and COX-2 appear to play a significant role. COX-1 is considered a constitutive enzyme, found in most tissues, including gastrointestinal mucosa (Schorr 2009). COX-2, on the other hand, is undetectable in most normal tissues, with expression induced in areas of inflammation. More importantly, COX-2 been shown to be upregulated in various carcinomas and to have a central role in tumorigenesis (Chan et al. 2007). Nonetheless, there have been many COX-independent mechanisms proposed for aspirin’s anti-cancer benefit. Moreover, there remains a need to further elucidate downstream pathways of COX-2 that influence cancer.

In recent years, there has been a substantial new body of evidence demonstrating the potential of anti-inflammatory drugs as chemopreventive agents for colorectal cancer. This volume will review the current body of evidence for aspirin in sporadic neoplasia (Chap. 7, Rothwell) and hereditary cancers (Chap. 9, Burn) and NSAIDs (Chap. 5, Arber). We will also describe the many proposed anti-cancer mechanisms of NSAIDs and aspirin (Chap. 3, Patrigan; Chap. 2, Dixon; Chap. 4, Rodriguez; and Chap. 6, Piazza) and the evidence for the use of alternative agents with similar anti-inflammatory mechanisms of action (Chap. 8, Hull). Taken together, this volume will provide several different perspectives that

demonstrate the emerging role of anti-inflammatory agents for chemoprevention for CRC and other chronic diseases.

References

- Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. *N Engl J Med* 355(9):885–895
- Avivi D, Moshkowitz M, Detering E, Arber N (2012) The role of low-dose aspirin in the prevention of colorectal cancer. *Expert Opin Ther Targets* PMID 22313430 1:s51–s62
- Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 348(10):891–899
- Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. *Gastroenterology* 125(2):328–336
- Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. *N Engl J Med* 355(9):873–884
- Burn J, Bishop DT, Chapman PD et al (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. *Cancer Prev Res (Phila)* 4(5):655–665
- Burn J, Gerdes AM, CAPP2 investigators (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 378(9809):2081–2087.
- Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. *JAMA* 294(8):914–923
- Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N Engl J Med* 356:2131–2142
- Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. *Gastroenterology* 134(1):21–28
- Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. *JAMA* 302(6):649–658
- Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM (2012) The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for the prevention of colorectal adenoma. *Cancer Prev Res* PMID: 22313430 5(1):61–72
- Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. *J Natl Cancer Inst* 101:256–266
- Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hyland LM, Celano P et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med* 328:1313–1316
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: <http://globocan.iarc.fr>, accessed on 02/02/2011
- Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E et al (2003) Rofecoxib reduces polyp recurrence in familial polyposis. *Dig Dis Sci* 48:1998–2002
- Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR (2008) Group uT. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. *Gastroenterology* 134(1):29–38
- Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP et al (2012) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *The Lancet* PMID 22440694 376(9754):1741–1750

- Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 377(9759):31–41
- Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* 348(10):883–890
- Schror K (2009) Acetylsalicylic acid. Blackwell, Germany
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 342:1946–1952
- Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* 231(25):232–235
- Vane JR (1982) Adventures and excursions in bioassay: the stepping stones to prostaglandins. Nobel lecture, 8 December PMID 6360277

Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia

Dan A. Dixon, Fernando F. Blanco, Annalisa Bruno
and Paola Patrignani

Abstract

The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step of prostaglandin formation in pathogenic states and a large amount of evidence has demonstrated constitutive COX-2 expression to be a contributing factor promoting colorectal cancer (CRC). Various genetic, epigenetic, and inflammatory pathways have been identified to be involved in the etiology and development of CRC. Alteration in these pathways can influence COX-2 expression at multiple stages of colon carcinogenesis allowing for elevated prostanoid biosynthesis to occur in the tumor microenvironment. In normal cells, COX-2 expression levels are potently regulated at the post-transcriptional level through various RNA sequence elements present within the mRNA 3' untranslated region (3'UTR). A conserved AU-rich element (ARE) functions to target COX-2 mRNA for rapid decay and translational inhibition through association with various RNA-binding proteins to influence the fate of COX-2 mRNA. Specific microRNAs (miRNAs) bind regions within the COX-2 3'UTR and control COX-2 expression. In this chapter, we discuss novel insights in the mechanisms of altered post-transcriptional regulation of COX-2 in CRC and

D. A. Dixon (✉) · F. F. Blanco
Department of Cancer Biology, University of Kansas Medical Center,
Kansas, KS 66106, USA
e-mail: ddixon3@kumc.edu

A. Bruno
Center of Excellence on Aging (CeSI) and Department of Medicine and Aging,
G. d'Annunzio University, School of Medicine, Via dei Vestini 31, 66100 Chieti, Italy

P. Patrignani (✉)
Center of Excellence on Aging (CeSI) and Department of Neuroscience and Imaging,
G. d'Annunzio University, School of Medicine, Via dei Vestini 31, 66100 Chieti, Italy
e-mail: ppatrignani@unich.it

how this knowledge may be used to develop novel strategies for cancer prevention and treatment.

Abbreviations

CRC	Colorectal cancer
CV	Cardiovascular
CIN	Chromosomal instability
APC	Adenomatous polyposis coli
FAP	Familial adenomatous polyposis
EGF	Epidermal growth factor
TGF	Transforming growth factor
COX	Cyclooxygenase
PG	Prostaglandin
(TX) _{A2}	Thromboxane
PGI ₂	Prostacyclin
GI	Gastrointestinal
NSAIDs	Nonsteroidal anti-inflammatory drugs
mPGES	Microsomal Prostaglandin E Synthase
15-PGDH	15-hydroxyprostaglandin dehydrogenase
PPAR	Peroxisome proliferator-activated receptor
AU	Rich elements (AREs)
miRNAs	MicroRNAs
HuR	Hu antigen R
TIA-1	T cell intracellular antigen 1
RBM3	RNA-binding motif protein 3

Contents

1	Molecular Basis of Colorectal Adenoma and Carcinoma	9
1.1	Genetic Basis of Adenoma-Carcinoma Sequence	9
1.2	Adenomatous Polyposis Coli	10
1.3	The Microsatellite Instability Pathway in CRC	11
1.4	The Epigenetic Pathway in CRC	12
1.5	COX-2/mPGES-1 Pathway	12
1.6	Prostaglandin Transporters in CRC	16
1.7	Epidermal Growth Factor Receptor Pathway	16
1.8	Peroxisome Proliferator-Activated Receptors	17
1.9	Tumor Microenvironment in Colorectal Carcinogenesis	18
2	COX-2 Gene Expression in CRC	18
2.1	Transcriptional Regulation	19
2.2	Post-transcriptional Regulation and the 3' Untranslated Region	21
2.3	AU-Rich Elements and ARE-Binding Proteins	22
2.4	MicroRNAs	26
3	Conclusions	29
	References	30